查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1718069

按检测类型、癌症类型、技术、付款来源、应用程式和最终用户分類的多癌症筛检市场—2025 年至 2030 年全球预测

Multicancer Screening Market by Test Type, Cancer Type, Technology, Payment Source, Application, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计多癌筛检市场规模在 2024 年将达到 15.3 亿美元，在 2025 年将达到 16.7 亿美元，在 2030 年将达到 27.2 亿美元，复合年增长率为 10.05%。

主要市场统计数据
基准年2024年 15.3亿美元
预计2025年 16.7亿美元
预测年份 2030 27.2亿美元
复合年增长率（%） 10.05%

近年来，医疗保健领域在癌症早期发现和管理方面取得了重大进展。多重癌症筛检是基因组学、诊断学和临床研究交叉领域的一个快速增长的领域，它正在改变临床医生进行癌症检测的方式。这项新模式旨在利用先进技术和综合诊断平台来更全面地了解潜在的恶性肿瘤。

越来越多的研究支持早期诊断、风险评估和个人化治疗策略，推动了多癌症筛检的发展。该领域的创新者不断筛检通讯协定，以提高准确性并减少假阳性。因此，患者将受益于更个人化和及时的干预，从而改善整体治疗效果。

先驱研究和临床检验强调了准确的分子分析和多种诊断测试整合的重要性。这些进步不仅增强了临床决策能力，而且为侵入性较小、可高度预测癌症存在的诊断筛检方法铺平了道路。继续重视早期发现将有助于提高存活率和更有效地分配医疗资源，标誌着精准医疗过程中的重要里程碑。

重新定义多癌症筛检的变革性转变

该领域最近的转型变化从根本上重新定义了行业标准和市场动态。下一代定序、质谱和聚合酵素链锁反应等技术突破将诊断准确性推向了新的高度。除了这些进步之外，人们越来越依赖实验室开发的测试和液态切片技术，这些技术正在改变临床医生检测和监测癌症生物标记的方式。

筛检技术的进步与医疗保健重点向早期发现和预防保健的广泛转变相辅相成。目前，重点是开发能够在低丰度生物标记场景中实现快速週转时间和高灵敏度的平台。此外，新的遗传和分子生物分析的整合促进了对癌症异质性的更细緻的理解。这将导致更精确的风险分层，这在考虑不同癌症类型及其相应治疗方案之间的复杂相互作用时至关重要。

随着情势的不断变化，相关人员越来越意识到利用这些创新所需的策略必要事项。显然，对尖端诊断工具和综合筛检通讯协定的投资不仅使临床实践现代化，而且还有助于实现强调早期疗育而非传统反应策略的模式转移。

多癌症筛检市场的关键细分洞察

对多癌症筛检市场的全面分析揭示了多方面的细分见解，这对于理解当前的行业动态至关重要。按测试类型细分包括对基因组、实验室开发的测试和液态切片的严格评估。这些诊断方法为癌症检测提供了多种方法，每种方法都利用独特的生物标记和技术细节来帮助制定早期疗育策略。研发和产业专家指出，基因组提供了识别易感性和突变所必需的基因蓝图，实验室开发的测试允许进行客製化评估和实验室定义的参数，液态切片具有微创性并可快速获得结果。

以癌症类型分类，检查的癌症包括乳癌、大肠癌、白血病、肺癌、特异性多器官癌和摄护腺癌。癌症类型的多样性需要彻底了解其各自的生物机制和诊断挑战。此外，按技术细分显示，已经引入了质谱、微阵列、次世代定序和聚合酵素链锁反应等各种平台，每个平台都在精确地推进这一领域的发展。这些技术提供了不同的方法来量化生物标记和了解基因图谱，有助于客製化治疗方法。

市场也根据付款来源进行细分，透过支付来源评估诊断解决方案，包括政府补贴、自付、私人健康保险等。这种细分凸显了影响市场采用和可近性的经济和政策影响。诊断筛检分为早期发现和风险评估，预后预测分为病患监测、治疗选择和治疗效果评估。在研究应用领域，专注于生物标记发现和基因研究的子区隔正在成为持续创新的催化剂。最后，最终用户细分包括门诊手术中心、诊断中心、医院、研究机构和专科诊所，突显了多癌症筛检技术在不同医疗保健环境中的广泛部署。

这些细分洞察提供了对市场驱动因素和障碍的详细了解，帮助相关人员根据影响当前格局的各种诊断、技术和经济因素做出明智的决策。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 癌症发生率上升和人口老化
      • 医疗成本上涨和政府倡议
      • 早期检测对于改善患者预后越来越重要
    • 限制因素
      • 多重癌症筛检高成本
    • 机会
      • 非侵入性和微创筛检程序的开发
      • 巨量资料与数位健康平台的整合
    • 任务
      • 解决对足够安全性和有效性的担忧
  • 市场区隔分析
    • 测试类型：液态生物检体因其患者友善的样本采集过程而越来越受到青睐
    • 用途：扩大多癌种筛检在预测的应用
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

6. 多癌种筛检市场（依检测类型）

  • 介绍
  • 基因面板
  • 临床开发测试
  • 液态生物检体

7. 多重癌种筛检市场

  • 介绍
  • 乳癌
  • 大肠直肠癌
  • 白血病
  • 肺癌
  • 特异性多重器官癌症
  • 摄护腺癌

8. 多重癌种筛检市场（依技术）

  • 介绍
  • 质谱法
  • 微阵列
  • 下一代定序
  • 聚合酵素链锁反应

第九章 多癌种筛检市场（依付款来源）

  • 介绍
  • 政府补贴
  • 自费
  • 私人健康保险

第 10 章 多癌种筛检市场（依应用）

  • 介绍
  • 诊断筛检
    • 早期检测
    • 风险评估
  • 预后
    • 病患监测
    • 治疗方法方案
    • 治疗效果评估
  • 研究用途
    • 生物标记发现
    • 基因研究

第 11 章 多癌种筛检市场（依最终使用者）

  • 介绍
  • 门诊手术中心
  • 诊断中心
  • 医院
  • 研究所
  • 专科诊所

12. 美洲多癌筛检市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

13. 亚太地区多癌症种筛检市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

14. 欧洲、中东和非洲多癌筛检市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十五章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • ANPAC Bio-Medical Science Co., Ltd.
  • Burning Rock BIoTech Limited
  • Caris Life Sciences
  • Coyne Medical Ltd.
  • Delfi Diagnostics, Inc.
  • Elypta AB
  • EpiCypher, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Foundation Medicine, Inc.
  • Freenome Holdings, Inc.
  • Fulgent Genetics, Inc.
  • Gene Solutions
  • Grail, LLC by Illumina, Inc.
  • Guangzhou AnchorDx Medical Co., Ltd.
  • Guardant Health, Inc.
  • Invitae Corporation
  • Laboratory Corporation of America Holdings
  • Lucence Health Inc.
  • Micronoma, Inc.
  • MiRXES Pte Ltd.
  • Myriad Genetics, Inc.
  • Natera, Inc.
  • Naveris, Inc.
  • NeoGenomics Laboratories
  • OneTest
  • Siemens Healthineers AG
  • StageZero Life Sciences. Ltd.
Product Code: MRR-5C6F41F5AFE7

The Multicancer Screening Market was valued at USD 1.53 billion in 2024 and is projected to grow to USD 1.67 billion in 2025, with a CAGR of 10.05%, reaching USD 2.72 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.53 billion
Estimated Year [2025] USD 1.67 billion
Forecast Year [2030] USD 2.72 billion
CAGR (%) 10.05%

In recent years, the healthcare arena has witnessed a significant evolution in the early detection and management of cancers. Multicancer screening, a burgeoning field at the intersection of genomics, diagnostics, and clinical research, is transforming the way clinicians approach cancer detection. This emerging paradigm seeks to offer more comprehensive insights into potential malignancies by leveraging advanced technologies and integrative diagnostic platforms.

The evolution of multicancer screening is driven by a growing body of research that supports early diagnosis, risk assessment, and tailored treatment strategies. Innovators in the field are continuously refining screening protocols to improve accuracy and reduce false positives. As a result, patients benefit from more personalized and timely interventions, which in turn enhance overall treatment outcomes.

Pioneering studies and clinical validations have underscored the importance of precise molecular profiling and the integration of multiple diagnostic tests. These advancements not only augment clinical decision-making but also pave the way for diagnostic screening methods that are both less invasive and highly predictive of cancer presence. The continued emphasis on early detection contributes to improved survival rates and a more efficient allocation of healthcare resources, marking a critical milestone in the journey toward precision medicine.

Transformative Shifts Redefining the Multicancer Screening Landscape

Recent transformative shifts within the field have fundamentally redefined industry standards and market dynamics. Technological breakthroughs such as next-generation sequencing, mass spectrometry, and polymerase chain reaction have propelled diagnostic accuracy to new heights. These advancements are complemented by a growing reliance on laboratory developed tests and liquid biopsy techniques that are changing the way clinicians detect and monitor cancer biomarkers.

The evolution in screening technologies is closely linked with a broader shift in healthcare priorities toward early detection and preventive care. Emphasis is now placed on developing platforms that allow for rapid turnaround times and higher sensitivity in low-volume biomarker scenarios. Furthermore, integration of novel genetic and molecular analyses has facilitated a more nuanced understanding of cancer heterogeneity. This, in turn, enables more accurate risk stratification, which is vital when considering the complex interplay between various cancer types and corresponding treatment options.

As the landscape continues to adapt, stakeholders are increasingly aware of the strategic imperatives required to harness these innovations. It is clear that investments in state-of-the-art diagnostic tools and comprehensive screening protocols are not only modernizing clinical practices but are also contributing to a paradigm shift that emphasizes early intervention over conventional reactive strategies.

Key Segmentation Insights in the Multicancer Screening Market

A comprehensive analysis of the multicancer screening market reveals multifaceted segmentation insights central to understanding current industry dynamics. The segmentation based on test type includes a rigorous evaluation of gene panels, laboratory developed tests, and liquid biopsies. These diagnostic modalities offer diverse approaches to cancer detection, each leveraging unique biomarkers and technological nuances to support early intervention strategies. Researchers and industry experts note that gene panels provide a genetic roadmap that is essential for identifying predispositions and mutations, while laboratory developed tests allow for tailored assessments and laboratory-defined parameters, and liquid biopsies minimize invasiveness with rapid results.

When segmented by cancer type, the market research scrutinizes an array of cancers including breast, colorectal, leukemia, lung, non-specific multi-organ cancers, and prostate cancer. The diversity within cancer types necessitates a robust understanding of the biological mechanisms at play and the variable diagnostic challenges associated with each category. Furthermore, segmentation based on technology introduces a spectrum of platforms such as mass spectrometry, microarray, next-generation sequencing, and polymerase chain reaction, each advancing the field with precision. These technologies offer different approaches to quantifying biomarkers and understanding genetic profiles, which aids in tailoring treatment regimens.

The market is also segmented by payment source where diagnostic solutions are evaluated within frameworks that include government subsidies, out-of-pocket payments, and private health insurance. This segmentation underscores the economic and policy influences governing market adoption and accessibility. Additionally, segmentation by application brings forth insights under diagnostic screening, prognostics, and research applications, with diagnostic screening further differentiated by early detection and risk assessment, and prognostics divided into patient monitoring, therapy selection, and treatment efficacy assessment. Within the realm of research applications, sub-segmentations focus on biomarker discovery and genetic research, thereby serving as a catalyst for continuous innovation. Lastly, categorization based on the end user includes ambulatory surgical centers, diagnostic centers, hospitals, research institutions, and specialty clinics, highlighting the broad deployment of multicancer screening technologies across diverse healthcare settings.

Together, these segmentation insights provide a detailed understanding of market drivers and barriers, empowering stakeholders to make informed decisions based on varying diagnostic, technological, and economic factors that shape the current landscape.

Based on Test Type, market is studied across Gene Panel, Laboratory Developed Test, and Liquid Biopsy.

Based on Cancer Type, market is studied across Breast Cancer, Colorectal Cancer, Leukemia, Lung Cancer, Non-Specific Multi-Organ Cancer, and Prostate Cancer.

Based on Technology, market is studied across Mass Spectrometry, Microarray, Next - Generation Sequencing, and Polymerase Chain Reaction.

Based on Payment Source, market is studied across Government Subsidies, Out-of-Pocket Payment, and Private Health Insurance.

Based on Application, market is studied across Diagnostic Screening, Prognostics, and Research Applications. The Diagnostic Screening is further studied across Early Detection and Risk Assessment. The Prognostics is further studied across Patient Monitoring, Therapy Selection, and Treatment Efficacy Assessment. The Research Applications is further studied across Biomarker Discovery and Genetic Research.

Based on End User, market is studied across Ambulatory Surgical Centers, Diagnostic Centers, Hospitals, Research Institutions, and Specialty Clinics.

Regional Insights Shaping the Global Multicancer Screening Market

Regional dynamics play a crucial role in steering the multicancer screening market, with distinct trends emerging across various geographies. In the Americas, increased funding for research, supportive regulatory frameworks, and a strong emphasis on early detection have collectively accelerated the adoption of advanced screening technologies. An ecosystem enriched by academic collaborations and public-private partnerships is fostering the rapid integration of these diagnostics into routine clinical practice.

Across Europe, the Middle East, and Africa, the landscape is simultaneously evolving with an emphasis on harmonized healthcare practices and large-scale government interventions targeted at disease prevention. The region has seen a progressive push towards the implementation of precision screening, driven by both rising cancer incidences and increasing awareness regarding early diagnosis. Meanwhile, the Asia-Pacific region has emerged as an influential player, characterized by rapid economic growth, technological advancements, and broad patient accessibility. Investment in state-of-the-art diagnostic centers and the ongoing integration of innovative testing methodologies are establishing a robust market presence that is poised for sustainable growth.

Collectively, these regional insights emphasize the global nature of the market and highlight the varying pace at which different regions are adapting to and adopting the transformative potential of multicancer screening technologies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Driving Innovation in Multicancer Screening

The multicancer screening market is marked by the active participation of several trailblazing companies whose innovations drive the industry's momentum. Noteworthy players such as ANPAC Bio-Medical Science Co., Ltd. and Burning Rock Biotech Limited have carved out critical niches by offering advanced diagnostic tests and comprehensive genomic analyses. Organizations like Caris Life Sciences and Coyne Medical Ltd. have significantly influenced cancer diagnostics by integrating cutting-edge bioinformatics with traditional laboratory operations.

Other key industry leaders, including Delfi Diagnostics, Inc. and Elypta AB, are leveraging novel molecular profiling techniques to enhance early detection and risk assessment capabilities. EpiCypher, Inc., Epigenomics AG, and Exact Sciences Corporation have also played pivotal roles by further refining the accuracy of diagnostic platforms while expanding the scope of genetic screening. Foundation Medicine, Inc., Freenome Holdings, Inc., and Fulgent Genetics, Inc. have introduced innovative testing protocols that incorporate multi-dimensional data analysis and refined patient stratification. Companies such as Gene Solutions and Grail, LLC by Illumina, Inc. have demonstrated expertise in combining robust research with clinical applications.

Further contributions from Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, and Laboratory Corporation of America Holdings underscore an industry-wide commitment to precision and efficiency. In addition, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., and Myriad Genetics, Inc. have set benchmarks for integrating streamlined diagnostics with next-generation treatment selections. The market continues to benefit from the diverse contributions of Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Their collective expertise fosters a competitive environment that fuels ongoing advancements in early cancer screening and personalized medicine applications.

The report delves into recent significant developments in the Multicancer Screening Market, highlighting leading vendors and their innovative profiles. These include ANPAC Bio-Medical Science Co., Ltd., Burning Rock Biotech Limited, Caris Life Sciences, Coyne Medical Ltd., Delfi Diagnostics, Inc., Elypta AB, EpiCypher, Inc., Epigenomics AG, Exact Sciences Corporation, Foundation Medicine, Inc., Freenome Holdings, Inc., Fulgent Genetics, Inc., Gene Solutions, Grail, LLC by Illumina, Inc., Guangzhou AnchorDx Medical Co., Ltd., Guardant Health, Inc., Invitae Corporation, Laboratory Corporation of America Holdings, Lucence Health Inc., Micronoma, Inc., MiRXES Pte Ltd., Myriad Genetics, Inc., Natera, Inc., Naveris, Inc., NeoGenomics Laboratories, OneTest, Siemens Healthineers AG, and StageZero Life Sciences. Ltd.. Actionable Recommendations for Industry Leaders

Industry leaders are encouraged to drive further innovation by investing in research and development that spans the full spectrum of diagnostic modalities. It is advisable to enhance collaborations between clinical research institutions and diagnostic companies to accelerate the translation of novel biomarkers into clinically actionable tools. Strategic investments in technologies such as next-generation sequencing, mass spectrometry, and polymerase chain reaction will provide the robust framework required for developing more precise screening solutions.

Stakeholders should also consider leveraging real-world evidence and comprehensive market segmentation data when tailoring product offerings to the evolving needs of diverse patient populations. Engaging with regulatory bodies to streamline approval processes and actively participating in public health initiatives can foster a more supportive environment for rapid adoption and scaling of multicancer screening programs. The effective integration of digital health tools and real-time data analytics into diagnostic platforms is another pertinent recommendation that can improve patient monitoring and treatment efficacy assessments. Overall, a proactive approach backed by agile decision-making and strategic foresight is essential to stay ahead in this competitive and ever-evolving market.

Conclusion: Embracing Innovation and Precision in Cancer Screening

In summary, the multicancer screening market reflects a transformative period marked by rapid technological advancements and sophisticated segmentation models. Detailed analysis across diverse diagnostic methods, cancer types, and technological applications reveals an industry that is not only dynamic but also deeply committed to early and precise detection. The global regional insights further emphasize the necessity of customized approaches tailored to specific market dynamics, while leading company innovations set the stage for further breakthroughs. The ongoing focus on precision medicine underlines the importance of continuous research and collaborative efforts, ensuring that advancements in diagnostic tools translate into improved patient outcomes and enhanced clinical practices.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disease and rising aging population
      • 5.1.1.2. Rise in healthcare expenditure and government initiative
      • 5.1.1.3. Growing emphasis on early detection for improved patient outcomes
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with multicancer screening
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of non-invasive and minimally invasive screening procedures
      • 5.1.3.2. Integration of big data and digital health platforms
    • 5.1.4. Challenges
      • 5.1.4.1. Addressing concerns associated with adequate safety and efficacy
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Test Type: Increasing preference for liquid biopsy due to its patient-friendly sample collection process
    • 5.2.2. Application: Expanding application of multicancer screening in prognostics
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Multicancer Screening Market, by Test Type

  • 6.1. Introduction
  • 6.2. Gene Panel
  • 6.3. Laboratory Developed Test
  • 6.4. Liquid Biopsy

7. Multicancer Screening Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Colorectal Cancer
  • 7.4. Leukemia
  • 7.5. Lung Cancer
  • 7.6. Non-Specific Multi-Organ Cancer
  • 7.7. Prostate Cancer

8. Multicancer Screening Market, by Technology

  • 8.1. Introduction
  • 8.2. Mass Spectrometry
  • 8.3. Microarray
  • 8.4. Next - Generation Sequencing
  • 8.5. Polymerase Chain Reaction

9. Multicancer Screening Market, by Payment Source

  • 9.1. Introduction
  • 9.2. Government Subsidies
  • 9.3. Out-of-Pocket Payment
  • 9.4. Private Health Insurance

10. Multicancer Screening Market, by Application

  • 10.1. Introduction
  • 10.2. Diagnostic Screening
    • 10.2.1. Early Detection
    • 10.2.2. Risk Assessment
  • 10.3. Prognostics
    • 10.3.1. Patient Monitoring
    • 10.3.2. Therapy Selection
    • 10.3.3. Treatment Efficacy Assessment
  • 10.4. Research Applications
    • 10.4.1. Biomarker Discovery
    • 10.4.2. Genetic Research

11. Multicancer Screening Market, by End User

  • 11.1. Introduction
  • 11.2. Ambulatory Surgical Centers
  • 11.3. Diagnostic Centers
  • 11.4. Hospitals
  • 11.5. Research Institutions
  • 11.6. Specialty Clinics

12. Americas Multicancer Screening Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Multicancer Screening Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Multicancer Screening Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Function Health partners with GRAIL to expand Galleri multi-cancer early detection test access
    • 15.3.2. Lucence and DxD Hub partner to enhance multi-cancer detection through alternative sample testing
    • 15.3.3. Freenome secures USD 254 million funding to advance multi-cancer blood tests and drive early detection innovations
    • 15.3.4. PanGIA Biotech Advances Multi-Cancer Detection with Liquid Biopsy Platform
    • 15.3.5. Introduction of Riskguard, A Hereditary Cancer Screening Test by Exact Sciences Corp
    • 15.3.6. Strategic Partnership Between SeekIn Inc. and Oncolnv to Enhance Global Cancer Detection Efforts
    • 15.3.7. Collaboration Between AnchorDx and DiaCarta to Revolutionize Global Cancer Screening
    • 15.3.8. Burning Rock Biotech Achieves Global Recognition with OverC Multi-Cancer Detection Blood Test
    • 15.3.9. Elypta Attains ISO 13485:2016 Certification, Advancing GAGome-Based Multicancer Detection
    • 15.3.10. Strategic Acquisition by Freenome Amplifies Cancer Screening Capabilities through Oncimmune Ltd's Advanced Diagnostics
    • 15.3.11. Lucence Advances Cancer Detection with Innovative MCED Blood Test: A Strategic Unveiling in the U.S.
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. ANPAC Bio-Medical Science Co., Ltd.
  • 2. Burning Rock Biotech Limited
  • 3. Caris Life Sciences
  • 4. Coyne Medical Ltd.
  • 5. Delfi Diagnostics, Inc.
  • 6. Elypta AB
  • 7. EpiCypher, Inc.
  • 8. Epigenomics AG
  • 9. Exact Sciences Corporation
  • 10. Foundation Medicine, Inc.
  • 11. Freenome Holdings, Inc.
  • 12. Fulgent Genetics, Inc.
  • 13. Gene Solutions
  • 14. Grail, LLC by Illumina, Inc.
  • 15. Guangzhou AnchorDx Medical Co., Ltd.
  • 16. Guardant Health, Inc.
  • 17. Invitae Corporation
  • 18. Laboratory Corporation of America Holdings
  • 19. Lucence Health Inc.
  • 20. Micronoma, Inc.
  • 21. MiRXES Pte Ltd.
  • 22. Myriad Genetics, Inc.
  • 23. Natera, Inc.
  • 24. Naveris, Inc.
  • 25. NeoGenomics Laboratories
  • 26. OneTest
  • 27. Siemens Healthineers AG
  • 28. StageZero Life Sciences. Ltd.

LIST OF FIGURES

  • FIGURE 1. MULTICANCER SCREENING MARKET MULTI-CURRENCY
  • FIGURE 2. MULTICANCER SCREENING MARKET MULTI-LANGUAGE
  • FIGURE 3. MULTICANCER SCREENING MARKET RESEARCH PROCESS
  • FIGURE 4. MULTICANCER SCREENING MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 23. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 27. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 28. MULTICANCER SCREENING MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 29. MULTICANCER SCREENING MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. MULTICANCER SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL MULTICANCER SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MULTICANCER SCREENING MARKET DYNAMICS
  • TABLE 7. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENE PANEL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LABORATORY DEVELOPED TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LIQUID BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NON-SPECIFIC MULTI-ORGAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY NEXT - GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY OUT-OF-POCKET PAYMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PRIVATE HEALTH INSURANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY EARLY DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PATIENT MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY THERAPY SELECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY TREATMENT EFFICACY ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY GENETIC RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL MULTICANCER SCREENING MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 63. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 64. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 65. ARGENTINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 72. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 73. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 74. BRAZIL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 79. CANADA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. CANADA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 81. CANADA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 82. CANADA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 83. CANADA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 88. MEXICO MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. MEXICO MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 90. MEXICO MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 91. MEXICO MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES MULTICANCER SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 117. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 166. MALAYSIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 174. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 175. PHILIPPINES MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 182. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 183. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. SINGAPORE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 191. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 192. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. SOUTH KOREA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 198. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 200. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 201. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 202. TAIWAN MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 207. THAILAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. THAILAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 209. THAILAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 210. THAILAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. THAILAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 216. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 218. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 219. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 220. VIETNAM MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 227. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 228. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 229. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 230. EUROPE, MIDDLE EAST & AFRICA MULTICANCER SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 235. DENMARK MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 236. DENMARK MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 237. DENMARK MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 238. DENMARK MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 239. DENMARK MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 244. EGYPT MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 245. EGYPT MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 246. EGYPT MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 247. EGYPT MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 248. EGYPT MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 253. FINLAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. FINLAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 255. FINLAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 256. FINLAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 257. FINLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 262. FRANCE MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 263. FRANCE MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 264. FRANCE MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 265. FRANCE MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 266. FRANCE MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 271. GERMANY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 272. GERMANY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 273. GERMANY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 274. GERMANY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. GERMANY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 280. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 282. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 283. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. ISRAEL MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 289. ITALY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 290. ITALY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 291. ITALY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 292. ITALY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 293. ITALY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 298. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 299. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 300. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 301. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 302. NETHERLANDS MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 307. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 308. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 309. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 310. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 311. NIGERIA MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 316. NORWAY MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. NORWAY MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 318. NORWAY MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 319. NORWAY MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 320. NORWAY MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 325. POLAND MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 326. POLAND MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 327. POLAND MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 328. POLAND MULTICANCER SCREENING MARKET SIZE, BY RESEARCH APPLICATIONS, 2018-2030 (USD MILLION)
  • TABLE 329. POLAND MULTICANCER SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR MULTICANCER SCREENING MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR MULTICANCER SCREENING MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR MULTICANCER SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR MULTICANCER SCREENING MARKET SIZE, BY PAYMENT SOURCE, 2018-2030 (USD MILLION)
  • TABLE 334. QATAR MULTICANCER SCREENING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 335. QATAR MULTICANCER SCREENING MARKET SIZE, BY DIAGNOSTIC SCREENING, 2018-2030 (USD MILLION)
  • TABLE 336. QATAR MULTICANCER SCREENING MARKET SIZE, BY PROGNOSTICS, 2018-2030 (USD MILLION)
  • TABLE 337. QATAR MULTICANCER SCREENING MARKET SIZE, B